1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Anew Medical, Inc.

Anew Medical, Inc.

WENAW
Anew Medical, Inc.US flagNASDAQ Global Market
0.04
USD
+0.00
- -
681,444.00Market Cap
Anew Medical, Inc.
WENAW
(NASDAQ Global Market)

Recent

price

0.04

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
FRC
- -
- -
Revenue per Share
- -
- -
Basic EPS, GAAP
- -
- -
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
- -
- -
Book Value per Share
- -
- -
Tangible Book Value per Share
- -
- -
Basic Weighted Avg Shares
- -
- -
Sales/Revenue/Turnover
- -
- -
Operating Margin (%)
- -
- -
Depreciation Expense
-1
-1
Net Income, GAAP
- -
- -
Effective Tax Rate (%)
- -
- -
Profit Margin (%)
- -
-1
Working Capital
- -
- -
LT Debt
1
1
Total Equity
- -
- -
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
14.89%
Free Cash Flow
- -
- -
155.26%
Net Income, GAAP
- -
- -
-46.03%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Theseus Pharmaceuticals, Inc. (THRX)
Coeptis Therapeutics Holdings, Inc. (COEPW)
Theralink Technologies, Inc. (OBMP)
D. Western Therapeutics Institute, Inc. (4576.T)
EvoNext Holdings S.A. (0QQJ.L)
Stayble Therapeutics AB (publ) (STABL.ST)
Business
Anew Medical, Inc. (NasdaqCM: WENAW) develops cell, gene, and protein therapies targeting neurodegenerative diseases and age-related disorders; its lead platform centers on proprietary secreted Klotho (s-KL) protein and gene therapies delivered via adeno-associated virus (AAV) vectors for central nervous system concentration to treat amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, dementia symptoms, and neuromuscular conditions; additional assets include worldwide rights to melanocortin receptor peptides modulating hunger, food intake, and weight loss, Nanoject dry-nanoparticle powder injection system for self-administration of insulin, GLP-1 agonists, vaccines, and biologics, generic oncology drugs addressing U.S. shortages, and Phase 3-ready biosimilars for cancer and autoimmune diseases. Founded in 1982 and headquartered in Omaha, Nebraska, with offices in the U.S. and Spain, the company operates primarily in the biotechnology sector serving global patient populations through partnerships with institutions like Universitat Autònoma de Barcelona and Japan's Okinawa Research Center for Klotho research. In June 2024, Anew Medical completed its business combination with Redwoods Acquisition Corp., enabling Nasdaq listing under tickers WENA and WENAW to advance gene therapy programs; the company secured a key patent in China in March 2024 for Klotho protein and gene delivery in neurodegenerative treatments; earlier, in December 2022, it acquired an exclusive worldwide license for the alpha-Klotho platform from Spanish institutions.